MedTrace Logo

Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese

NCT04185454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-01-11

No results posted yet for this study

Summary

Aim: To estimate an oral administered recommended minimum efficacy daily dose (MED) of Jarlsberg cheese in order to obtain the needed increased level of Osteocalcin defined as the ratio \[Carboxylated / Under Carboxylated\] Osteocalcin.

Study population: Healthy Voluntary (HV) women between 20 years and pre-menopausal age.

Design: Open and randomised two-dimensional single-centre trial with 3-level between-patient Response Surface Pathway (RSP) design in the first dimension and 3-level within-patient RSP design in the secondary dimension.

Conditions

Interventions

DIETARY_SUPPLEMENT

Jarlsberg cheese

Daily intake of Jarlsberg cheese

Sponsors & Collaborators

  • Tine

    collaborator INDUSTRY

  • Prof Stig Larsen

    lead OTHER

Principal Investigators

  • Helge Lundberg, MD · Skjetten Legesenter

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-04-15
Completion
2019-04-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04185454 on ClinicalTrials.gov